On August 18, 2017, the Patent Trial and Appeal Board (PTAB) ruled in favor of Finnegan client AstraZeneca, finding that Mylan Pharmaceuticals and other drug companies failed to show parts of AstraZeneca's patent covering its diabetes drugs Onglyza and Kombiglyze were invalid. The PTAB said it wasn't convinced someone experienced in pharmaceutical chemistry would have reasonably expected to have success making modifications to known compounds to arrive at those claimed in AstraZeneca’s patent. It also said there were additional considerations, including the failure of other compounds to obtain approval from the U.S. Food and Drug Administration for the treatment of diabetes, weighed against finding the patent claims obvious.